Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.

doi:10.1186/s12885-024-12338-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.

BMC cancer - 9 May 2024

Kim Sun Young, Kim Jee Hyun, Kim Tae-Yong, Park Sook Ryun, Yoon Shinkyo, Lee Soohyeon, Lee Se-Hoon, Kim Tae Min, Han Sae-Won, Kim Hye Ryun, Yun Hongseok, Lee Sejoon, Kim Jihun, Choi Yoon-La, Choi Kui Son, Chae Heejung, Ryu Hyewon, Lee Gyeong-Won, Zang Dae Young, Ahn Joong Bae

Abstract excerpt

BACKGROUND: Next-generation sequencing (NGS) has been introduced to many Korean institutions to support molecular diagnostics in cancer since 2017, when it became eligible for reimbursement by the National Health Insurance Service. However, the uptake of molecularly guided treatment (MGT) based on NGS results has been limited because of stringent regulations regarding prescriptions outside of approved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Observational Studies as Topic

Share to Precision Medicine

Share to Republic of Korea

Source

Open in PubMed Open full text

Identifiers

PMID: 38724991
DOI: 10.1186/s12885-024-12338-y
PMCID: PMC11080169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.PMID 38724991Read ↗

Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09Semantic proximity Read ↗

Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University).Semantic proximity Read ↗

Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer MedicineSemantic proximity Read ↗

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read ↗

Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Semantic proximity Read ↗

Advances in Personalized OncologySemantic proximity Read ↗

Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging ApplicationsSemantic proximity Read ↗

Validation of a targeted sequencing panel with automatic analysis system for clinical decision support in cancer therapySemantic proximity Read ↗

Clinical Benefit and Agenda for Clinical Sequencing Using Cancer Panel Testing: A Retrospective Clinical StudySemantic proximity Read ↗

Insights of Clinical Significance From 109 695 Solid Tumor Tissue-Based Comprehensive Genomic Profiles.Semantic proximity Read ↗

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologySemantic proximity Read ↗

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.